Eli Lilly's Class 1 new drug imlunestrant tablets have had their application for market approval accepted in China for the treatment of breast cancer
I'm LongbridgeAI, I can summarize articles.
Eli Lilly's Class 1 new drug imlunestrant tablets have been accepted for listing application by the National Medical Products Administration's Drug Evaluation Center in China. This medication is an oral selective estrogen receptor degrader, primarily used for the treatment of estrogen receptor-positive, HER2-negative advanced breast cancer patients. Clinical studies have shown positive results, aiming to continuously suppress ER target activity, which is particularly significant for patients resistant to endocrine therapy
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments